Therefore, in our study, we matched patient samples with normal controls for age and sex, and designed a two-stage experiment with the verification cohort and the validation cohort to explore whether anti-CXCL8 autoantibody could be used as a diagnostic indicator for ESCC. Here, CXCL8 is linked to esophageal squamous cell carcinoma.